Information for Vermont Prescribers of Prescription Drugs

SOFOSBUVIR-VELPATASVIR (sofosbuvir/velpatasvir) Tablets VOSEVI® (sofosbuvir/velpatasvir/voxilaprevir) Tablets

- This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.
- The prices listed below are Average Wholesale Prices ("AWP") as established and made available to the public by a third party publisher or as calculated from data made available to the public by a third party publisher.* The price paid by consumers may be higher or lower than the prices listed below. Information about AWP of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.**
- The prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed. For simplicity, only the smallest package sizes available for each product are included.

| Product Name | | | Manufacturer | NDC or UPC | Pkg Size | Pack | Unit |
|------------------------|----------------------|-------------------|-----------------|---------------|------------------|-------------|------------|
| | Marketed Product | | | | | | |
| Sofosbuvir-Velpatasvir | 400 mg-100 mg | Tablet | Asegua Therapeu | 72626-2701-01 | 28 EA | \$9,600.00 | \$342.86 |
| Vosevi | 400 mg-100 mg-100 mg | Tablet | Gilead Sciences | 61958-2401-01 | 28 EA | \$29,904.00 | \$1,068.00 |
| | Other Products | | | | | | |
| Epclusa | 200 mg-50 mg | Tablet | Gilead Sciences | 61958-2203-01 | 28 EA | \$29,904.00 | \$1,068.00 |
| Epclusa | 400 mg-100 mg | Tablet | Gilead Sciences | 61958-2201-01 | 28 EA | \$29,904.00 | \$1,068.00 |
| Epclusa | 150 mg-37.5 mg | Pellets In Packet | Gilead Sciences | 61958-2205-01 | Non-Pill Product | | |
| Epclusa | 200 mg-50 mg | Pellets In Packet | Gilead Sciences | 61958-2204-01 | Non-Pill Product | | |
| Harvoni | 45 mg-200 mg | Tablet | Gilead Sciences | 61958-1803-01 | 28 EA | \$37,800.00 | \$1,350.00 |
| Harvoni | 90 mg-400 mg | Tablet | Gilead Sciences | 61958-1801-01 | 28 EA | \$37,800.00 | \$1,350.00 |
| Harvoni | 33.75 mg-150 mg | Pellets In Packet | Gilead Sciences | 61958-1805-01 | Non-Pill Product | | |
| Harvoni | 45 mg-200 mg | Pellets In Packet | Gilead Sciences | 61958-1804-01 | Non-Pill Product | | |
| Ledipasvir-Sofosbuvir | 90 mg-400 mg | Tablet | Asegua Therapeu | 72626-2601-01 | 28 EA | \$14,400.00 | \$514.29 |
| Mavyret | 100 mg-40 mg | Tablet | Abbvie Us Llc | 00074-2625-84 | 84 EA | \$15,840.00 | \$188.57 |
| Mavyret | 50 mg-20 mg | Pellets In Packet | Abbvie Us Llc | 00074-2600-28 | Non-Pill Product | | |
| Sovaldi | 200 mg | Tablet | Gilead Sciences | 61958-1503-01 | 28 EA | \$33,600.00 | \$1,200.00 |
| Sovaldi | 400 mg | Tablet | Gilead Sciences | 61958-1501-01 | 28 EA | \$33,600.00 | \$1,200.00 |
| Sovaldi | 150 mg | Pellets In Packet | Gilead Sciences | 61958-1504-01 | Non-Pill Product | | |
| Sovaldi | 200 mg | Pellets In Packet | Gilead Sciences | 61958-1505-01 | Non-Pill Product | | |
| Zepatier | 50 mg-100 mg | Tablet | Merck Sharp & D | 00006-3074-02 | 14 EA | \$4,368.00 | \$312.00 |

For more information about First Databank's Drug Pricing Policy, visit http://www.fdbhealth.com/policies/drug-pricing-policy/

- Wholesale Acquisition Cost (WAC) plus 20%,
- If WAC is not available, Direct Price (DP) plus 20%
- If neither WAC nor DP is available, Suggested Wholesale Price (SWP)

^{*}Prices shown are calculated using the following methodology as per the updated guidance provided by Vermont in September 2011 for pharmaceutical marketers who use First Databank data:

^{**}Therapeutic Class is defined as the American Hospital Formulary Service (AHFS) Pharmacologic-Therapeutic Classification, published by the American Society of Health System Pharmacists.